Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Brefeldin A is a lactone macrolide natural product originally isolated from the fungus Penicillium brefeldianum. It is primarily used as a research tool rather than as an approved pharmaceutical. Mechanistically, it blocks Sec7 domain-containing guanine nucleotide exchange factors (GEFs), which are necessary for activation of ADP-ribosylation factor 1 (Arf1), thereby preventing COP-I coat assembly on Golgi membranes and disrupting vesicular trafficking. This leads to rapid tubulation and fusion of the Golgi with the ER and inhibits secretion in eukaryotic cells[1][5][6]. Brefeldin A also induces apoptosis in certain cell types and has been shown to inhibit intracellular collagen degradation and apical sodium channels in epithelia[5][6]. While initially investigated for antiviral activity due to its broad antibiotic properties—including antifungal and antitumor effects—its poor efficacy limited clinical development; it remains widely used in cell biology research for studying membrane traffic dynamics[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on brefeldin a.